FY2026 Earnings Estimate for VRTX Issued By Erste Group Bank

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Erste Group Bank raised their FY2026 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the pharmaceutical company will post earnings of $16.93 per share for the year, up from their previous estimate of $16.91. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $17.01 per share. Erste Group Bank also issued estimates for Vertex Pharmaceuticals’ FY2027 earnings at $18.97 EPS.

Other equities analysts also recently issued reports about the stock. Morgan Stanley raised their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Royal Bank Of Canada increased their target price on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wall Street Zen cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Sanford C. Bernstein decreased their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a research report on Tuesday, May 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $559.61.

Vertex Pharmaceuticals Stock Performance

Shares of NASDAQ VRTX opened at $485.65 on Friday. The company’s fifty day moving average is $462.54 and its two-hundred day moving average is $459.00. Vertex Pharmaceuticals has a one year low of $362.50 and a one year high of $533.67. The firm has a market capitalization of $123.26 billion, a P/E ratio of 28.80, a PEG ratio of 2.11 and a beta of 0.29.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. The firm had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $2.99 billion. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. Vertex Pharmaceuticals’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.06 EPS.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total value of $787,485.00. Following the completion of the sale, the executive vice president owned 45,321 shares in the company, valued at $23,793,071.79. This represents a 3.20% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total value of $3,144,600.00. Following the completion of the transaction, the chief marketing officer owned 26,088 shares in the company, valued at $11,739,600. This represents a 21.13% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 18,874 shares of company stock valued at $8,707,966 in the last three months. Insiders own 0.20% of the company’s stock.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Community Financial Services Group LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $26,000. Motiv8 Investments LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth about $26,000. Elevation Wealth Partners LLC grew its stake in shares of Vertex Pharmaceuticals by 103.7% during the second quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 28 shares during the last quarter. Swiss RE Ltd. bought a new position in Vertex Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Eagle Bay Advisors LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $29,000. 90.96% of the stock is currently owned by institutional investors.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.